Sigma Medex

Trustiva belongs to the class of antiretroviral medications used as a triple combination against HIV-1 infected patients over 12 years of age. Trustiva consists of three molecules tenofovir disoproxil fumarate (TDF) 300 mg, Efavirenz (EFV) 600 mg and Emtricitabine (FTC) 200 mg, indicated as a complete regimen. The molecules are mixed in a fixed-dose combination (FDC). The FDC drug is not used for complete cure of HIV but prevents the virus from multiplying in the system.

Trustiva (TDF 300 mg + EFV 600 mg + FTC 200 mg) is taken orally once daily on an empty stomach at bedtime for avoiding instances of unnecessary nervous system symptoms. It is recommended in patients with at least 40 kgs of body weight. In few cases, if patients weigh more than 50 kgs and rifampin is co-administered along with Trustiva (TDF 300 mg + EFV 600 mg + FTC 200 mg), 200 mg/day of efavirenz is added. Trustiva (TDF 300 mg + EFV 600 mg + FTC 200 mg) is strictly prohibited in patients with kidney problems (renal impairment with creatine clearance below 50 mL/min).